PATENT CLAIM ANALYSIS

Application Number: 16227810
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "133100"]

Abstract:
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Claim (Index 149):
The method of  claim 147 , wherein the human IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked, with or without a linker, to an IL-23p19 polypeptide.

Metadata:
- Claim Count in Document: 79.0
- Percentile: 98.0
- Lexical Diversity: 1.73684
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16184282', '16222155', '15995889', '16219418', '15996146']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8665220000939571
- 35 USC 102 Novelty (BERT): 0.6765161316143582
- Combined Prediction Score: 0.8475214132459973
- Mean Citation Score: 671.050294
- Max Citation Score: 719.048
- Similarity Product: 657.0146757607462

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test